After more than two decades as a Big Pharma cancer leader, Nicholas Botwood is swinging into the biotech world as the new ...

BioMarin has followed through on its shift to external innovation, inking a deal to buy Inozyme for $270 million to add a phase 3 enzyme replacement therapy to its pipeline.